Two recipients of orthotopic heart transplantation have all recovered from their serious heart disease and returned to their previous work with good condition for 3 and 1 year respectively.This article discusses with emphasis some steps happened before,during and after the operation of heart transplantation,especially the donor heart protection,immunosuppressant administration,diagnosis and treatment of rejection.

Objective To study the anti acute rejection effect of ethanol extract of poria cocos wolf (EEPCW) in heart transplantation rats.Methods Homologous heart transplanted rats were divided into 4 groups ( n =20 in each group). EEPCW 50?mg?kg -1 ?d -1 , EEPCW 25?mg?kg -1 ?d -1 , CsA 5?mg?kg -1 ?d -1 and olive oil 8?ml?kg -1 ?d -1 were given to different groups. Cardiac allograft survival was observed on 10 of each groups. The pathologic lesion, the contents of IL 2 and IFN ? in peripheral blood, percentage of CD3 +, CD4 +, CD8 + lymphocytes and ratio of CD4 +/CD8 + were determined on another 10 in each groups and 10 normal rats. Results Survival of the donor heart was significantly prolonged and pathologic lesion was relieved, the contents of IL 2 and IFN ? in peripheral blood, percentage of CD3 +, CD4 +, CD8 + lymphocytes and ratio of CD4 +/CD8 + were significantly reduced in EEPCW groups.Conclusion Acute rejection of heart transplantation can be effectively suppressed by ethanol extract of poria cocos wolf.

Objective To study the isolation and phenotype of peripheral blood pDC 1 and pDC 2 in rhesus monkey.Methods Peripheral blood monoclear cells (PBMCs) were isolated from healthy, SIV-negative rhesus monkeys (M.mulatta) using Ficoll-Hypaque density separation. DC precursors were identified and were sorted by 3 color rare-event cytometric flow analysis using human monoclonal antibodies cross reactive with rhesus monkey. Results DC subsets were identified within the lineage- HLA-DR+ fraction of PBMCs and maintained activities. Myeloid DC (pDC 1) showed the phenotype lineage-, HLA-DR+ and BDCA 1+; Lymphoid DC (pDC 2)showed the phenotype lineage-, HLA-DR+ and CD123+ (IL-3R?+).Conclusions We have identified the rhesus monkey pDC 1 and pDC 2 similar to those from human beings. Identification of pDC 1 and pDC 2 is an important first step towards testing of these important immunomodulatory APC in the therapy of allograft rejection in non-human primates.

Objective To study the effects of administration of donor apoptotic bone marrow cells via portal vein on the survival time of heart transplantation in rats.Methods Wistar rats were selected as donors and SD rats as recipients, and divided into 4 groups at random. In groups A, B and C, the animals were injected via portal vein with RPMI 1640 0.5 ml 6 as control group, 5?107 donor bone marrow cells and 5?107 apoptotic donor bone marrow cells 6 days before transplantation, respectively , and not subjected to cyclosporin A (CsA). In group D, the animals were injected intra- peritoneally with CsA 5 mg/kg from 3 days before transplantation till 10 days post operation. Bone marrow cells apoptosis was induced by 60 Co? radiation. Heart transplantation models were established in each group. The survival time of donor heart and histological changes were observed. Serum concentrations of IL-10 and TGF-?_1 of recipients and mixed lymphocyte reaction (MLR) were measured. Results The survival time of heart allografts in the group C ( 14.00 ? 0.95 ) was significantly longer than in group A (P

[Summary] This review summarized the evolution of surgical timing and procedure skills of postnatal repair in the treatment of congenital diaphragmatic hernia ( CDH ) .Minimally invasive repair of diaphragmatic hernia was highlighted.The current status, difficulties, and future trends of surgical intervention for CDH were analyzed.

Objective:To investigate the effect of Duhuo Jisheng Decoction on early cartilage destruction markers in patients with rheumatoid arthritis with kidney-qi deficiency and cold syndrome.Methods:A total of 64 patients with rheumatoid arthritis in our hospital from March 2019 to March 2020 who met the inclusion criteria were divided into 2 groups, according to the random number table method, with 32 in each group. The control group was given conventional western medicine therapy, and the observation group was given Duhuo Jisheng decoction on the basis of the control group. Both groups were treated for 8 weeks. TCM syndrome scores were performed before and after treatment, serum CRP, IL-6, cartilage oligosaccharide protein (COMP) and β-catenin were detected by ELISA method, and adverse eventns during treatment were observed and compared. The clinical efficacy was evaluated.Results:The total effective rate was 87.5% (28/32) in the observation group and 65.6% (21/32) in the control group, and the difference between the two groups was statistically significant ( χ2=4.27, P=0.039). After treatment, the main symptoms, secondary symptoms and tongue and pulse scores of the observation group were significantly lower than those in the control group ( t=7.11, 3.11, 2.41, P<0.01 or P<0.05); serum CRP and IL-6 levels were significantly lower than those in the control group ( t=3.04, 4.56, P<0.01); serum COMP [(12.37±1.68) μg/L vs. (14.24±1.88) μg/L, t=4.20], β-catenin [(1.35±0.24) μg/L vs. (1.68±0.31) μg/L, t=4.76] levels were significantly lower than those in the control group ( P<0.01). During the treatment, the incidence of adverse events was 25.0% (8/32) in the observation group and 18.8% (6/32) in the control group, and there was no significant difference between the two groups ( χ2=0.37, P=0.546). Conclusion:The Duhuo Jisheng Decoction can help to reduce the levels of inflammatory cytokines and early cartilage destruction markers in patients with rheumatoid arthritis, and improve the clinical efficacy safely.

Objective To investigate the prenatal imaging features of fetal congenital esophageal atresia and to further evaluate the value of MRI and ultrasound scan in the same condition.Methods This study recruited 12 singleton gravidas whose fetuses were initially suspected with congenital esophageal atresia by prenatal ultrasound scan and then confirmed by surgery and/or upper gastrointestinal angiography after birth at Guangzhou Women and Children's Medical Center from May 2011 to May 2017.Imaging features of prenatal MRI and ultrasonography of the 12 fetuses were retrospectively analyzed.Differences in imaging findings of these two methods were analyzed by Chi-square test.Results All 12 women received prenatal ultrasound examination and eight of them underwent MRI scan when fetal congenital esophageal atresia was suggested by ultrasound.Both ultrasound and MRI were capable of identifing polyhydramnios and absent or small stomach bubble (12/12 and 8/8,respectively).However,MRI was superior to ultrasound in detecting "pouch sign "/"oral filling sign" or poor filling of small intestine (7/8 vs 3/12 and 8/8 vs 0/12,x2 were 7.500 and 20.000,both P＜0.01).While,no statistical difference was shown in detecting curved tracheal between MRI and ultrasound (2/8 vs 0/12,x2=3.333,P=0.067).For Gross Ⅰ or Gross Ⅲ congenital esophageal atresia fetuses,no statistically significant difference was found in their imaging features (all P＞0.05).The total detection rates after 32 weeks of gestation of Gross Ⅰ and Gross Ⅲ cases were both 3/6.Conclusions Prenatal MRI is a vital supplement to ultrasound due to its high display rate of characterized features of congenital esophageal atresia.Thus,the combined use of ultrasound and MRI is of great importance for prenatal diagnosis of this fetal abnormality.

Because of the unsatisfactory treatment options for breast cancer (BC), there is a need to develop novel therapeutic approaches for this malignancy. One such strategy is chemotherapy using non-toxic dietary substances and botanical products. Studies have shown that Panduratin A (PA) possesses many health benefits, including anti-inflammatory, anti-bacterial, anti-oxidant and anti-cancer activities. In the present study, we provide evidence that PA treatment of MCF-7 BC cells resulted in a time- and dose-dependent inhibition of cell growth with an IC50 of 15 µM and no to little effect on normal human MCF-10A breast cells. To define the mechanism of these anti-proliferative effects of PA, we determined its effect critical molecular events known to regulate the cell cycle and apoptotic machinery. Immunofluorescence and flow cytometric analysis of Annexin V-FITC staining provided evidence for the induction of apoptosis. PA treatment of BC cells resulted in increased activity/expression of mitochondrial cytochrome C, caspases 7, 8 and 9 with a significant increase in the Bax:Bcl-2 ratio, suggesting the involvement of a mitochondrial-dependent apoptotic pathway. Furthermore, cell cycle analysis using flow cytometry showed that PA treatment of cells resulted in G0/G1 arrest in a dose-dependent manner. Immunoblot analysis data revealed that, in MCF-7 cell lines, PA treatment resulted in the dose-dependent (i) induction of p21WAF1/Cip1 and p27Kip1, (ii) downregulation of Cyclin dependent kinase (CDK) 4 and (iii) decrease in cyclin D1. These findings suggest that PA may be an effective therapeutic agent against BC.
Apoptosis* ; Breast Neoplasms* ; Breast* ; Caspases ; Cell Cycle Checkpoints* ; Cell Cycle* ; Cell Proliferation* ; Cyclin D1 ; Cyclins ; Cytochromes c ; Down-Regulation ; Drug Therapy ; Flow Cytometry ; Fluorescent Antibody Technique ; Humans ; Inhibitory Concentration 50 ; Insurance Benefits ; MCF-7 Cells ; Phosphotransferases

We report the clinical features of a case of congenital extralobar pulmonary sequestration in the left upper lobe supplied by the pulmonary artery. Prenatal ultrasound examination at 24 weeks of gestation revealed a high echogenic and uniform density mass in the fetal left thoracic cavity with the congenital pulmonary airway malformation volume vatio (CVR) of 1.16, which was supplied by pulmonary arterial vessels. MRI examination at 27 weeks indicated that the left lung volume increased to about 48.52 ml, while the right lung volume was about 8.56 ml giving the total lung volume of 57.08 ml. The congenital pulmonary airway malformation in the left upper lobe was suspected to be congenital bronchial atresia (CBA) or congenital lobar overinflation (CLO). The baby boy was born through vaginal delivery assisted by forceps at 38 +1 weeks without neonatal asphyxia. Postnatal CT and MRI were both indicated suspicious bronchial atresia in the left upper lobe. Bronchofibroscopy on postnatal day 2 excluded CBA or CLO and extralobar pulmonary sequestration was considered. Thoracoscopic surgery was performed due to continuous shortness of breath after birth, despite two-week conservative treatment including oxygenation, invasive and non-invasive mechanical ventilation,etc, and congenital extralobar sequestration was diagnosed. Blood supply from the left pulmonary artery was observed at the base of abnormal lung tissue. Resection of the pathogenic tissue of the left lung was performed thoracoscopically. The boy recovered and was discharged after the operation. Pulmonary sequestration was confirmed by histopathology.

We report the clinical characteristics of congenital malignant rhabdoid tumor (MRT) of the neck in a fetus. Prenatal ultrasound and MRI at 33 +4 and 34 weeks gestation revealed a round solid mass on the right side of the fetus' neck. An initial differential diagnosis was between neuroblastoma and vascular malformation. Re-examination with ultrasound at 36 gestational weeks revealed an enlarged fetal neck mass, with concomitant multiple subcutaneous solid masses all over his body, right-side hydrothorax, and abnormal liver echo, which were highly suspicious of metastasis of a malignant tumor. The baby boy was delivered by cesarean section at 37 weeks of gestation with a normal Apgar score and slight shortness of breath. Physical examination showed scattered lesions in the neck, armpits, and limbs, etc. The condition of the infant deteriorated rapidly with the increasing number and volume of the masses after admission. The boy was confirmed as MRT (stage Ⅳ) by pathological biopsy on the left upper arm and died on postnatal day 10 after treatment was withdrawn.